Table 1.
Baseline characteristics and frequencies of CYP2C19 and ABCB1 genotypes in 51 neonates
| n | % | Mean (SD) | Median (range) | |
|---|---|---|---|---|
| Patients | 51 | |||
| Sex | 24M/27F | |||
| Gestational age at birth (weeks) | 31 (3.9) | 31 (24–41) | ||
| Current weight (g) | 2108 (609) | 2130 (780–3800) | ||
| PNA (days) | 41 (21) | 38 (7–87) | ||
| Omeprazole dose (mg/d) | 3.5 (1.6) | 3.6 (0.8–7.3) | ||
| Omeprazole dose (mg/kg/d) | 1.7 (0.6) | 2.0 (1.0–2.5) | ||
| CYP2C19 | ||||
| Poor metabolizer (PM) | ||||
| *2/*2 | 2 | 3.9 | ||
| Intermediate metabolizer (IM) | ||||
| *1/*2 | 7 | 13.7 | ||
| *2/*17 | 4 | 7.8 | ||
| Extensive metabolizer (EM) | ||||
| *1/*1 | 21 | 41.2 | ||
| Ultrarapid metabolizer (UM) | ||||
| *1/*17 | 14 | 27.5 | ||
| *17/*17 | 3 | 5.9 | ||
| ABCB1 | ||||
| C1236T | ||||
| C/C | 27 | 52.9 | ||
| C/T | 21 | 41.2 | ||
| T/T | 3 | 5.9 | ||
| G2677T/A | ||||
| G/G | 34 | 66.7 | ||
| G/T | 15 | 29.4 | ||
| G/A | ‐ | ‐ | ||
| T/T | 1 | 2.0 | ||
| T/A | 1 | 2.0 | ||
| C3435T | ||||
| C/C | 25 | 49.0 | ||
| C/T | 22 | 43.1 | ||
| T/T | 4 | 7.8 |